HERTRAZ 440MG INJECTION

Hertraz 440mg Injection is a prescription monoclonal antibody therapy containing trastuzumab, a targeted treatment for HER2-positive breast cancer and HER2-positive gastric cancer. This injectable therapy binds specifically to HER2 receptors on cancer cells, blocking growth signals and helping to control tumor progression. Hertraz 440 mg is administered via intravenous infusion under the supervision of a qualified oncologist to ensure safety and optimal results.

Trastuzumab in Hertraz 440 mg works by both inhibiting cancer cell growth and activating immune-mediated destruction of malignant cells. This dual action helps slow tumor progression, improves response to therapy, and enhances overall treatment outcomes. Hertraz 440 mg Injection is widely used in oncology centers as part of targeted therapy regimens for patients with HER2-overexpressing tumors.

Hertraz 440 mg Injection ensures high standards of quality, safety, and efficacy. It is a prescription-only oncology medicine intended for intravenous use in hospital settings. Hertraz 440 mg provides a clinically proven, trusted solution for patients with HER2-positive breast cancer and HER2-positive gastric cancer, supporting effective cancer management when used as part of a comprehensive treatment plan.

Product Features

• Targeted monoclonal antibody therapy
• Contains Trastuzumab 440 mg
• Used in HER2-positive cancers
• Intravenous infusion formulation
• High specificity against HER2 receptors
• Suitable for hospital and clinical oncology use
• Manufactured under GMP standards
• Prescription-required anticancer injection

How It Helps

• Specifically targets HER2 receptors to block cancer cell growth
• Activates immune-mediated destruction of malignant cells
• Helps slow or stop the progression of breast and gastric cancers
• Supports effective hospital-based targeted therapy under an oncologist’s supervision